The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market has grown fiercer.
Category: Novo Nordisk A/S
-
Why Patients Are Being Forced to Switch to a 2nd-Choice Obesity Drug
CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed by insurance that disrupt treatments for patients.
-
Patients Cut Off From Cheaper Obesity Drugs as FDA Halts Sales of Copycats
U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or suspend treatment for patients.
-
Weight Loss Drug Will Be Offered for $499 a Month for Some Patients
Some commercially insured patients stand to save $150 per month on Wegovy, a popular obesity medication. Patients on Medicare and Medicaid are not eligible.
-
Novo Nordisk Annual Sales Jump on Demand for Ozempic and Wegovy
The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year.
-
Medicare to Negotiate Lower Prices for Weight-Loss Drugs
The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide whether to expand coverage for millions of Americans.
-
U.S. Unveils Price Limits for 10 Costly or Common Medications
The Biden administration said it would have saved $6 billion had the new prices been in effect last year.
-
U.S. to Announce Prices for First Drugs Picked for Medicare Negotiations
The Biden administration said it would have saved $6 billion had the new prices been in effect last year.
-
How Ozempic Is Transforming a Small Danish Town
In Kalundborg, population under 17,000, Novo Nordisk is making huge investments to increase production of its popular diabetes and weight-loss drugs, Ozempic and Wegovy.
-
Inside Novo Nordisk, the Company Behind Ozempic and Wegovy
Novo Nordisk’s factories work nonstop turning out Ozempic and Wegovy, its blockbuster weight-loss drugs, but the Danish company has far bigger ambitions.
-
How Ozempic Turned a 1974 Hit Into an Inescapable Jingle
The diabetes drug has become a phenomenon, and “Oh, oh, oh, Ozempic!” — a takeoff of the Pilot song “Magic” — has played a big part in its story.
-
Investors Shrug off Nvidia’s ‘A.I. Woodstock’
The chipmaker unveiled a new high-speed processor at its developer conference to power an “industrial revolution,” but its sky-high valuation is coming under scrutiny.